Dominique PV de Kleijn,
Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute,
University Medical Center Utrecht, The Netherlands
Prof. Dr. Dominique PV de Kleijn is molecular biologist and chemist and professor of Exp. Vascular Surgery at UMC Utrecht and professor at the Netherlands Heart Institute. From 2012 to 2016, he was Research Professor of Surgery at NUS/NUHS and preclinical director of the Cardiovascular Research Institute (CVRI) Singapore. He was until 2016 professor of Cardiovascular Immunology and co-chair of Experimental Cardiology at UMC Utrecht. Since 1997 he is coordinating cardiovascular research from basic science, animal myocardial infarction and atherosclerotic studies (pig and sheep) towards clinical biobanking studies. His research interests are: The innate immune system in cardiovascular disease and atherosclerosis & Biomarkers predictive for primary & secondary events with a focus on plasma extracellular vesicles. He has more then 275 publications and a H-factor of 78.
Plasma Extracellular Vesicles in Cardiovascular Disease
Thursday, 26 September 2024 at 11:30
Add to Calendar ▼2024-09-26 11:30:002024-09-26 12:30:00Europe/LondonPlasma Extracellular Vesicles in Cardiovascular DiseaseEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com
Cardiovascular Disease (CVD) is with Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia.
Ischemic heart disease (IHD) comprises 2 entities: Chronic Coronary Syndrome (CCS) and Acute Coronary Syndrome (ACS). CCS is associated with 6-8 times increased risk of myocardial infarction and death. Chest pain is the symptom of patients that are suspected of CCS. But chestpain is very common (500.000 patients in NL/year) and only 10% have CCS. Since blood markers for CCS do not exist, this results in that 80-90% of chest pain patients that do not have CCS undergoing costly imaging. To reduce costs and make this diagnostic track much more efficient, we use plasma extracellular vesicle protein content of vesicles from plasma subfractions as an accurate source for exclusion of CCS. Using automated plasma EV fraction analysis and CD9 as an internal marker, but now also a microfluidics chip, we hope to establish a plasma EV test that will reduce unnecessary chestpain patient referral and therefore costs.
Add to Calendar ▼2024-09-26 00:00:002024-09-27 00:00:00Europe/LondonEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024Emerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-09-26 11:30:002024-09-26 12:30:00Europe/LondonPlasma Extracellular Vesicles in Cardiovascular DiseaseEmerging Technologies for Diagnostics and Liquid Biopsies - New Orleans 2024 in New OrleansNew OrleansSELECTBIOenquiries@selectbiosciences.com
